These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 20369716)

  • 1. [Results of anemia treatment with darbepoetin alfa and erythropoietin beta in patients with chronic kidney disease].
    Wanic-Kossowska M
    Pol Merkur Lekarski; 2010 Jan; 28(163):13-7. PubMed ID: 20369716
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Darbepoetin alfa administered every other week maintains hemoglobin levels over 52 weeks in patients with chronic kidney disease converting from once-weekly recombinant human erythropoietin: results from simplify the treatment of anemia with Aranesp (STAAR).
    Hertel J; Locay H; Scarlata D; Jackson L; Prathikanti R; Audhya P
    Am J Nephrol; 2006; 26(2):149-56. PubMed ID: 16636531
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Long-acting erythropoetin efficacy in the treatment of nephrogenic anemia in patients with chronic kidney disease during predialysis stage].
    Milovanov IuS; Milovanova LIu
    Ter Arkh; 2012; 84(6):48-52. PubMed ID: 22997919
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Multicenter study of darbepoetin alfa in the treatment of anemia secondary to chronic renal insufficiency on dialysis].
    Martínez Castelao A; Reyes A; Valdés F; Otero A; López de Novales E; Pallardó L; Tabernero JM; Hernández Jaras J; Lladós F
    Nefrologia; 2003; 23(2):114-24. PubMed ID: 12778875
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hemoglobin stability in patients with anemia, CKD, and type 2 diabetes: an analysis of the TREAT (Trial to Reduce Cardiovascular Events With Aranesp Therapy) placebo arm.
    Skali H; Lin J; Pfeffer MA; Chen CY; Cooper ME; McMurray JJ; Nissenson AR; Remuzzi G; Rossert J; Parfrey PS; Scott-Douglas NW; Singh AK; Toto R; Uno H; Ivanovich P
    Am J Kidney Dis; 2013 Feb; 61(2):238-46. PubMed ID: 23159232
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Darbepoetin alfa administration to achieve and maintain target hemoglobin levels for 1 year in patients with chronic kidney disease.
    Hertel JE; Locay HR; Scarlata DS; Prathikanti R; Audhya PK
    Mayo Clin Proc; 2006 Sep; 81(9):1188-94. PubMed ID: 16970215
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Darbepoetin-alfa treatment of anemia secondary to chronic renal failure in dialysis patients: Results of a French multicenter study].
    Kessler M; Hannedouche T; Fitte H; Cayotte JL; Urena P; Réglier JC;
    Nephrol Ther; 2006 Sep; 2(4):191-9. PubMed ID: 16966064
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Darbepoetin alfa effectively treats anemia in patients with chronic kidney disease with de novo every-other-week administration.
    Toto RD; Pichette V; Navarro J; Brenner R; Carroll W; Liu W; Roger S
    Am J Nephrol; 2004; 24(4):453-60. PubMed ID: 15331889
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A trial of subcutaneous administration of darbepoetin alfa once every other week for the treatment of anemia in peritoneal dialysis patients.
    Mahajan S; Boulton H; Gokal R
    J Nephrol; 2004; 17(5):687-92. PubMed ID: 15593036
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An open-label study of darbepoetin alfa administered once monthly for the maintenance of haemoglobin concentrations in patients with chronic kidney disease not receiving dialysis.
    Agarwal AK; Silver MR; Reed JE; Dhingra RK; Liu W; Varma N; Stehman-Breen C
    J Intern Med; 2006 Dec; 260(6):577-85. PubMed ID: 17116009
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reengineering clinical operations in a medical practice to optimize the management of anemia of chronic kidney disease.
    Joy MS; Candiani C; Vaillancourt BA; Chin H; Hogan SL; Falk RJ
    Pharmacotherapy; 2007 May; 27(5):734-44. PubMed ID: 17461709
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Darbepoetin alfa effectively maintains haemoglobin concentrations at extended dose intervals relative to intravenous or subcutaneous recombinant human erythropoietin in dialysis patients.
    Brunkhorst R; Bommer J; Braun J; Haag-Weber M; Gill C; Wagner J; Wagener T;
    Nephrol Dial Transplant; 2004 May; 19(5):1224-30. PubMed ID: 14993489
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Treatment of renal anemia with darbepoetin alfa: results of an Austrian multicenter study].
    Hörl WH; Holzer H; Mayer GJ;
    Wien Klin Wochenschr; 2002 Dec; 114(23-24):967-71. PubMed ID: 12635463
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Treatment of renal anemia with darbepoetin alfa administered once every other week in predialysis patients with chronic kidney disease and previously treated with epoetin alfa].
    Molina M; García Hernández MA; Navarro MJ; Pérez Silva F; Cacho M; De Gracia MC
    Nefrologia; 2004; 24(1):54-9. PubMed ID: 15083958
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients.
    Nissenson AR; Swan SK; Lindberg JS; Soroka SD; Beatey R; Wang C; Picarello N; McDermott-Vitak A; Maroni BJ
    Am J Kidney Dis; 2002 Jul; 40(1):110-8. PubMed ID: 12087568
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Changing the frequency of administration of darbepoetin alfa (from weekly to fortnightly) maintains the haemoglobin levels in patients undergoing peritoneal dialysis].
    Bajo MA; Pérez Fontán M; Remón C; Sánchez-Tomero JA; Lladós F; Selgas R
    Nefrologia; 2009; 29(2):136-42. PubMed ID: 19396319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized double-blind trial of darbepoetin alfa in patients with symptomatic heart failure and anemia.
    Ghali JK; Anand IS; Abraham WT; Fonarow GC; Greenberg B; Krum H; Massie BM; Wasserman SM; Trotman ML; Sun Y; Knusel B; Armstrong P;
    Circulation; 2008 Jan; 117(4):526-35. PubMed ID: 18195176
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of darbepoetin alfa and epoetin alfa in the management of anemia of critical illness.
    Voils SA; Harpe SH; Brophy GM
    Pharmacotherapy; 2007 Apr; 27(4):535-41. PubMed ID: 17381380
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dosing intervals and hemoglobin control in patients with chronic kidney disease and anemia treated with epoetin alfa or darbepoetin alfa: a retrospective cohort study.
    Nurko S; Spirko R; Law A; Dennis VW
    Clin Ther; 2007 Sep; 29(9):2010-21. PubMed ID: 18035200
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Evaluation of efficacy of darbepoetin alfa administered once monthly as treatment of anemia in predialysis patients with chronic kidney disease].
    Martínez PM; García de Vinuesa S; Ortega Díaz M; Goicoechea M; Gómez Campderá F; Luño J
    Nefrologia; 2005; 25(6):663-7. PubMed ID: 16514907
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.